• NeoGenomics priced a private offering of USD 275 million 0.75% convertible senior notes due 2032.
• Initial purchasers received an option for up to an additional USD 41.25 million, lifting potential proceeds to USD 316.25 million.
• Net proceeds estimated at USD 266.15 million, or USD 306.16 million if the option is exercised in full.
• Plans include about USD 25 million for capped calls, repurchase of USD 276 million 0.25% convertible senior notes due 2028, and up to USD 25 million of stock.
• Closing expected June 22, 2026.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. NeoGenomics Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 20260617584382) on June 17, 2026, and is solely responsible for the information contained therein.